Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis

Journal of Pineal Research

Volumn 45, Issue 2, 2008, Pages 166-173

  Esposito, Emanuela ^a,b   Mazzon, Emanuela ^b   Riccardi, Luisa ^c   Caminiti, Rocco ^d   Meli, Rosaria ^b   Cuzzocrea, Salvatore ^a,d  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Colon damage; Dinitrobenzene sulphonic acid; Free radicals; Inflammation; Metalloproteinase

Indexed keywords

DINITROBENZENE SULPHONIC ACID; GELATINASE A; GELATINASE B; MELATONIN; SULFONIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMICAL ANALYSIS; COLITIS; COLON; COLON INJURY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; LIPID PEROXIDATION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; ZYMOGRAPHY;

ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; COLITIS; DINITROFLUOROBENZENE; LIPID PEROXIDATION; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MELATONIN; RATS; RATS, SPRAGUE-DAWLEY; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49549087478     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2008.00572.x     Document Type: Article

References (68)

1. Castaneda FE, Walia B, Vijay-Kumar M et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005 129 : 1991 2008.
2. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002 3 : 207 214.
3. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004 16 : 558 564.
4. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001 17 : 463 516.
5. Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001 2 : 10 19.
6. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004 4 : 617 629.
7. Naito Y, Takagi T, Kuroda M et al. An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res 2004 53 : 462 468.
8. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005 26 : 379 390.
9. Medina C, Videla S, Radomski A et al. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 2003 284 : G116 G122.
10. Di Sebastiano P, Di Mola FF, Artese L et al. Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 2001 63 : 234 239.
11. Baugh MD, Perry MJ, Hollander AP et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 1999 117 : 814 822.
12. Baugh MD, Evans GS, Hollander AP et al. Expression of matrix metalloproteases in inflammatory bowel disease. Ann N Y Acad Sci 1998 859 : 249 253.
13. Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC, MacDonald TT. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol 1997 158 : 1582 1590.
14. Tarlton JF, Whiting CV, Tunmore D et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol 2000 157 : 1927 1935.
15. Seifert WF, Wobbes T, Hendriks T. Divergent patterns of matrix metalloproteinase activity during wound healing in ileum and colon of rats. Gut 1996 39 : 114 119.
16. Fu X, Kassim SY, Parks WC, Heinecke JW. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem 2001 276 : 41279 41287.
17. Swarnakar S, Mishra A, Ganguly K, Sharma AV. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J Pineal Res 2007 43 : 56 64.
18. English JL, Kassiri Z, Koskivirta I et al. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 2006 281 : 10337 10346.
19. Tan DX, Reiter RJ, Manchester LC et al. Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002 2 : 181 197.
20. Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995 9 : 526 533.
21. Allegra M, Reiter RJ, Tan DX, Gentile C, Tesoriere L, Livrea MA. The chemistry of melatonin's interaction with reactive species. J Pineal Res 2003 34 : 1 10.
22. Winiarska K, Fraczyk T, Malinska D, Drozak J, Bryla J. Melatonin attenuates diabetes-induced oxidative stress in rabbits. J Pineal Res 2006 40 : 168 176.
23. Gilad E, Cuzzocrea S, Zingarelli B, Salzman AL, Szabo C. Melatonin is a scavenger of peroxynitrite. Life Sci 1997 60 : PL169 PL174.
24. Cuzzocrea S, Zingarelli B, Gilad E, Hake P, Salzman AL, Szabo C. Protective effect of melatonin in carrageenan-induced models of local inflammation: relationship to its inhibitory effect on nitric oxide production and its peroxynitrite scavenging activity. J Pineal Res 1997 23 : 106 116.
25. Cuzzocrea S, Mazzon E, Serraino I et al. Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J Pineal Res 2001 30 : 1 12.
26. Fries W, Mazzon E, Squarzoni S et al. Experimental colitis increases small intestine permeability in the rat. Lab Invest 1999 79 : 49 57.
27. Wallace JL, Keenan CM, Gale D, Shoupe TS. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated leukotriene B4 synthesis. Gastroenterology 1992 102 : 18 27.
28. Miller MJ, Thompson JH, Zhang XJ et al. Role of inducible nitric oxide synthase expression and peroxynitrite formation in guinea pig ileitis. Gastroenterology 1995 109 : 1475 1483.
29. Zingarelli B, Squadrito F, Graziani P, Camerini R, Caputi AP. Effects of zileuton, a new 5-lipoxygenase inhibitor, in experimentally induced colitis in rats. Agents Actions 1993 39 : 150 156.
30. Diaz-Granados N, Howe K, Lu J, McKay DM. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000 156 : 2169 2177.
31. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979 95 : 351 358.
32. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980 102 : 196 202.
33. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 2001 53 : 135 159.
34. Grisham MB. Oxidants and free radicals in inflammatory bowel disease. Lancet 1994 344 : 859 861.
35. Rachmilewitz D, Stamler JS, Karmeli F et al. Peroxynitrite-induced rat colitis - a new model of colonic inflammation. Gastroenterology 1993 105 : 1681 1688.
36. Simmonds NJ, Allen RE, Stevens TR, Van Someren RN, Blake DR, Rampton DS. Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease. Gastroenterology 1992 103 : 186 196.
37. McKenzie SJ, Baker MS, Buffinton GD, Doe WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 1996 98 : 136 141.
38. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990 87 : 1620 1624.
39. Ischiropoulos H, Zhu L, Beckman JS. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992 298 : 446 451.
40. Mazzon E, Esposito E, Crisafulli C et al. Melatonin modulates signal transduction pathways and apoptosis in experimental colitis. J Pineal Res 2006 41 : 363 373.
41. Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
42. Reiter RJ, Tan DX, Poeggeler B, Menendez-Pelaez A, Chen LD, Saarela S. Melatonin as a free radical scavenger: implications for aging and age-related diseases. Ann N Y Acad Sci 1994 719 : 1 12.
43. Leon J, Acuna-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005 38 : 1 9.
44. Onuki J, Almeida EA, Medeiros MH, Di Mascio P. Inhibition of 5-aminolevulinic acid-induced DNA damage by melatonin, N1-acetyl-N2-formyl-5- methoxykynuramine, quercetin or resveratrol. J Pineal Res 2005 38 : 107 115.
45. Ganguly K, Maity P, Reiter RJ, Swarnakar S. Effect of melatonin on secreted and induced matrix metalloproteinase-9 and -2 activity during prevention of indomethacin-induced gastric ulcer. J Pineal Res 2005 39 : 307 315.
46. Jaworek J, Brzozowski T, Konturek SJ. Melatonin as an organoprotector in the stomach and the pancreas. J Pineal Res 2005 38 : 73 83.
47. Rosen J, Than NN, Koch D, Poeggeler B, Laatsch H, Hardeland R. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res 2006 41 : 374 381.
48. Chen HY, Chen TY, Lee MY et al. Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice. J Pineal Res 2006 41 : 175 182.
49. Garg P, Rojas M, Ravi A et al. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol 2006 177 : 4103 4112.
50. Gao Q, Meijer MJ, Kubben FJ et al. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005 37 : 584 592.
51. Giaever I, Keese CR. A morphological biosensor for mammalian cells. Nature 1993 366 : 591 592.
52. Lempinen M, Inkinen K, Wolff H, Ahonen J. Matrix metalloproteinases 2 and 9 in indomethacin-induced rat gastric ulcer. Eur Surg Res 2000 32 : 169 176.
53. Swarnakar S, Ganguly K, Kundu P, Banerjee A, Maity P, Sharma AV. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem 2005 280 : 9409 9415.
54. Ganguly K, Kundu P, Banerjee A, Reiter RJ, Swarnakar S. Hydrogen peroxide-mediated downregulation of matrix metalloprotease-2 in indomethacin-induced acute gastric ulceration is blocked by melatonin and other antioxidants. Free Radic Biol Med 2006 41 : 911 925.
55. Mori N, Sato H, Hayashibara T et al. Helicobacter pylori induces matrix metalloproteinase-9 through activation of nuclear factor kappaB. Gastroenterology 2003 124 : 983 992.
56. Carty E, De Brabander M, Feakins RM, Rampton DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000 46 : 487 492.
57. Negoro K, Kinouchi Y, Hiwatashi N et al. Crohn's disease is associated with novel polymorphisms in the 5′-flanking region of the tumor necrosis factor gene. Gastroenterology 1999 117 : 1062 1068.
58. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 1999 5 : 119 133.
59. Murthy S, Cooper HS, Yoshitake H, Meyer C, Meyer CJ, Murthy NS. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis. Aliment Pharmacol Ther 1999 13 : 251 260.
60. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 340 : 1398 1405.
61. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997 337 : 1029 1035.
62. van Dullemen HM, van Deventer SJ, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995 109 : 129 135.
63. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 1999 117 : 429 432.
64. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc 1999 50 : 667 671.
65. Baert FJ, D'Haens GR, Peeters M et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999 116 : 22 28.
66. Moreland LW, Margolies G, Heck LW Jr. et al. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 1996 23 : 1849 1855.
67. Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 1997 349 : 521 524.
68. Cuzzocrea S, Reiter RJ. Pharmacological actions of melatonin in acute and chronic inflammation. Curr Top Med Chem 2002 2 : 153 165.